

CORRECTION

Open Access



Correction to: Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France

Salim Mezaache^{1,2*}, Patrizia Carrieri^{1,2}, Laelia Briand-Madrid^{1,2}, Virginie Laporte³, Alain Morel⁴, Daniela Rojas Castro^{1,2,5} and Perrine Roux^{1,2}

Correction to: Mezaache et al. *Harm Reduct J* (2021) 18:11

<https://doi.org/10.1186/s12954-021-00460-0>

Following publication of the original article [1], the authors identified an error in Table 1.

The correct table is given below.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1186/s12954-021-00460-0>.

*Correspondence: salim.mezaache@inserm.fr

¹ INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sante & Traitement de L'information Medicale, Aix-Marseille Univ, Marseille, France
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Factors associated with general willingness to receive intravenous buprenorphine treatment in the study sample

	N (%) or Median [IQR]	Univariate analysis n = 209			Multivariate analysis n = 197		
		OR	[95CI%]	<i>p</i>	AOR	[95CI%]	<i>p</i>
Questionnaire							
Online	162 (78)	0					
Face-to-face	47 (22)	0.97	[0.53; 1.77]	0.924			
Gender							
Male	164 (79)	0					
Female	43 (21)	0.75	[0.41; 1.35]	0.335			
Age							
For 1 year	34 [28–41]	0.99	[0.96; 1.02]	0.619			
Stable housing							
No	81 (39)	0					
Yes	127 (61)	0.72	[0.43; 1.22]	0.228			
Employment							
No	147 (70)	0					
Yes	62 (30)	0.76	[0.44; 1.30]	0.319			
Duration of opioid use							
For 1 year	8 [4–11]	1.01	[0.96; 1.06]	0.614			
Duration of buprenorphine use							
For 1 year	6 [4–10]	1.02	[0.97; 1.07]	0.528			
Daily buprenorphine dose							
For 1 mg	11 [8–16]	1.04	[1.00; 1.09]	0.052	1.05	[1.00; 1.10]	0.043
Daily injection frequency							
For 1 injection	3 [2–4]	1.12	[0.98; 1.27]	0.086			
Buprenorphine non-prescribed							
No	187 (93)	0					
Yes	13 (7)	3.98	[1.09; 14.47]	0.036	4.82	[1.30; 17.85]	0.019
Main reason for injecting buprenorphine							
To get "high"	27 (15)	0					
To avoid withdrawal symptoms or to feel good enough for daily functioning	103 (59)	0.96	[0.44; 2.10]	0.929			
For the pleasure of the act	41 (23)	2.23	[1.08; 4.61]	0.030			
Other non-opioid drugs used							
No	49 (24)	0					
Yes	156 (76)	1.03	[0.56; 1.89]	0.934			
Alcohol consumption							
No	124 (59)	0					
Yes	85 (41)	0.99	[0.60; 1.67]	0.997			
Lifetime number of injection-related complications (0–10)							
≤ 5 complications	175 (84)	0					
> 5 complications	34 (16)	2.29	[1.08; 4.88]	0.031	2.28	[1.05; 4.93]	0.037
Lifetime history of overdose							
No	168 (80)	0					
Yes	41 (20)	1.26	[0.65; 2.47]	0.493			
Self-reported HCV status							
No	129 (66)	0					
Yes	66 (34)	0.87	[0.50; 1.53]	0.647			

Author details

¹ INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sante & Traitement de L'information Medicale, Aix-Marseille Univ, Marseille, France.
² ORS PACA, Observatoire Regional de La Sante Provence-Alpes-Cote D'Azur, Marseille, France. ³ Aides, Pantin, France. ⁴ Association Oppelia, Paris, France.
⁵ Laboratoire de Recherche Communautaire Coalition PLUS, Pantin, France.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 19 February 2021

Reference

1. Mezaache et al. *Harm Reduct J* (2021) 18:11. <https://doi.org/10.1186/s12954-021-00460-0>